Figure 5.
Figure 5. Reduced myeloid proliferation capacity of RPS19-deficient CD34+ BM cells. (A) Cell count at serial time points in myeloid liquid culture shows decreased proliferation capacity in RPS19-silenced CD34+GFP+ cells. Ten thousand cells were seeded at day 0. (B) Flow cytometry analysis of GFP-positive cells stained with CD13 and CD33 after 14 days in myeloid culture visualize 3 distinct cell populations: CD13- (gate 1), CD13+ (2), and CD13++ (3). All populations are positive for CD33. (C) The bar graphs show the percentage of GFP-positive cells within the 3 gates (CD13-, CD13+, and CD13++) after 14 days in myeloid culture. The means ± SEMs for 5 independent experiments are shown. *P < .05 compared with LV-TH-RPS19-Scr-transduced cells.

Reduced myeloid proliferation capacity of RPS19-deficient CD34+BM cells. (A) Cell count at serial time points in myeloid liquid culture shows decreased proliferation capacity in RPS19-silenced CD34+GFP+ cells. Ten thousand cells were seeded at day 0. (B) Flow cytometry analysis of GFP-positive cells stained with CD13 and CD33 after 14 days in myeloid culture visualize 3 distinct cell populations: CD13- (gate 1), CD13+ (2), and CD13++ (3). All populations are positive for CD33. (C) The bar graphs show the percentage of GFP-positive cells within the 3 gates (CD13-, CD13+, and CD13++) after 14 days in myeloid culture. The means ± SEMs for 5 independent experiments are shown. *P < .05 compared with LV-TH-RPS19-Scr-transduced cells.

Close Modal

or Create an Account

Close Modal
Close Modal